Lartruvo(olaratumab)

[Function and indication] Combined with doxorubicin for specific types of soft tissue sarcomas that are not suitable for radiotherapy or surgery but are suitable for anthracyclines

[Model and specification] Injection: 500 mg/50 mL (10 mg/mL)

[Usage and dosage] Administer LARTRUVO at 15 mg/kg by intravenous infusion over 60 minutes on days 1 and 8 of each 21-day treatment cycle until disease progression or unacceptable toxicity

[Adverse reactions] The most common (≥20%) adverse reactions of LARTRUVO plus doxorubicin are nausea, fatigue, musculoskeletal pain, mucositis, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy, and headache. The most common (≥20%) laboratory abnormalities are lymphopenia, neutropenia, thrombocytopenia, hyperglycemia, elevated aPTT, hypokalemia, and hypophosphatemia.

[Manufacturer] Eli Lilly